Novo Holdings A/S invests in US healthcare IT company Availity
Strategic health IT investment will strengthen payer-provider collaboration and reduce waste in … Continue reading “Novo Holdings A/S invests in US healthcare IT company Availity”
Strategic health IT investment will strengthen payer-provider collaboration and reduce waste in … Continue reading “Novo Holdings A/S invests in US healthcare IT company Availity”
STIMULAN® when mixed with antibiotics is the only calcium matrix approved for … Continue reading “Biocomposites announces new approval for STIMULAN® to treat bacterial infection”
Experienced Industry Leader with successful Oncology, Immunotherapy & ADC Development Track Record … Continue reading “Adcendo Appoints Michael Pehl as Chief Executive Officer”
GDT-002 is a potential first-in-class cellular immunotherapy UTRECHT, Netherlands and BOSTON, July 6, 2021 /PRNewswire/ — Gadeta … Continue reading “First Patient Dosed with Gadeta’s gamma delta TCR Cell Therapy”
Brighton, United Kingdom – 02 July 2021 – Destiny Pharma plc (AIM: DEST), a clinical … Continue reading “Destiny Pharma Scientific Advisor, Professor Dale Gerding, to chair C. diff. Foundation Symposium”
Bionical Solutions, a leading provider of technology enabled engagement and healthcare services … Continue reading “Bionical Solutions Appoints David Bournes As Business Development Director”
Salvia BioElectronics B.V. (“Salvia”), a neurostimulation platform company targeting chronic migraine, announces … Continue reading “Salvia BioElectronics appoints Dr Alan Levy as Chairman”
Brighton, United Kingdom – 29 June 2021 – Destiny Pharma plc (AIM: DEST), … Continue reading “Destiny Pharma to present at the Shares and AJ Bell Investor Webinar on 06 July 2021”
The objective is to make RNA therapeutics accessible to global patient populations. … Continue reading “eTheRNA immunotherapies and Quantoom Biosciences Announce a Strategic Collaboration for the Development of a Novel RNA Production System”
Extension to proven TriMix® adjuvant technology intended to boost dendritic cell activation Niel … Continue reading “eTheRNA and VUB expand strategic collaboration to engineer next generation mRNA therapeutics with TetraMix®”
• Artios’ small molecule Polθ inhibitor elicits BRCA-gene synthetic lethality and PARP … Continue reading “Artios Pharma Publishes Preclinical Data on The First Selective Small Molecule Polθ Polymerase Inhibitor in Nature Communications”
Novo Holdings A/S, a leading global life sciences investor, today announced it … Continue reading “Novo Holdings acquires BBI Group”
COPENHAGEN, Denmark, June 11, 2021 – Bavarian Nordic A/S (OMX: BAVA) announced today … Continue reading “Bavarian Nordic Assists Public Health England In Response To New Cases Of Monkeypox”
$40 million upfront including $25 million cash and $15 million in equity … Continue reading “Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China”
XF-73 met its primary end point with >99% nasal aureus reduction within 24 hours … Continue reading “Destiny Pharma: XF-73 data abstract to be presented at 2021 ECCMID”
vasopharm GmbH, a privately-held biopharmaceutical company focusing on novel therapeutics for the … Continue reading “vasopharm Announces Results of the Nostra III Traumatic Brain Injury Phase III Study”
Company co-created and funded by Novo Holdings and HealthCap Breakthrough asset in-licensed … Continue reading “Novo Seeds Launches Tribune Therapeutics to Develop Novel Medicines Targeting a Wide Range of Fibrotic Diseases”
Positive update on microbiome therapeutic NTCD-M3 for recurrent C. difficile infections · Preparations for … Continue reading “Destiny Pharma: Positive update on microbiome therapeutic NTCD-M3 for recurrent C. difficile infections”
Executive leadership and strategic focus strengthened for sustained company development 01 June … Continue reading “Macrophage Pharma Appoints Dr Venkat Reddy As Chief Executive Officer”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2021 Optimum Strategic Communications All rights reserved.
8 Devonshire Square
Spitalfields
London
EC2M 4PL
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com
